Last reviewed · How we verify

NCT06819488

A Clinical Study of Mass Balance of [14C]HRS-7535

Completed Phase 1 Last updated 7 May 2025
What this trial tests

Phase 1 trial testing [14C]HRS-7535 in Type 2 Diabetes Mellitus in 6 participants. Completed in 16 April 2025.

Timeline
27 February 2025
Primary endpoint
16 April 2025
16 April 2025

Quick facts

Lead sponsorShandong Suncadia Medicine Co., Ltd.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment6
Start date27 February 2025
Primary completion16 April 2025
Estimated completion16 April 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shandong Suncadia Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, male only, with Type 2 Diabetes Mellitus or Weight Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to evaluate the mass balance of \[14C\]HRS-7535 in healthy adult Chinese subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

Other Shandong Suncadia Medicine Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06819488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing